Skip to search formSkip to main contentSkip to account menu

AVE 0010

Known as: AVE-0010, AVE0010 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Lixisenatide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist… 
Review
2016
Review
2016
Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes:A Clinical Update of Safety and Efficacy
Abstract: Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly being used for the treatment of… 
2016
2016
Lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes… 
2014
2014
Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
This was a subanalysis of Japanese patients included in the glucagon‐like peptide‐1 receptor agonist AVE0010 in patients with… 
2010
2010
Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
2009
2009
Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin [Abstract]
Highly Cited
2008
Highly Cited
2008
Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues
We recently showed that insulin analogues exhibit a beta-cell protective function. The aim of this study was to test if the anti… 
2008
2008
Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.
2008
2008
The GLP–1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets [abstract]
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)